Key Points
- Insider Johannes Jacob Piete Kastelein sold 94,124 shares on March 6 at $30.32 for $2.85M and completed several other large sales in Jan–Mar, reducing his direct stake by about 57.6% to 69,302 shares.
- NewAmsterdam reported weak quarterly results (EPS -$0.63 vs. -$0.40 est., revenue $0.03M vs. $0.92M) and very negative margins, yet analysts retain a "Moderate Buy" consensus with an average price target of $47.10.
- Institutional investors own roughly 89.9% of the company, with major funds (e.g., Capital World, Jennison, Duquesne) materially increasing positions, indicating strong institutional backing despite insider sales and recent weak results.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 94,124 shares of NewAmsterdam Pharma stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.32, for a total transaction of $2,853,839.68. Following the transaction, the insider directly owned 69,302 shares in the company, valued at approximately $2,101,236.64. This represents a 57.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Johannes Jacob Piete Kastelein also recently made the following trade(s):
- On Monday, March 9th, Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61.
- On Thursday, March 5th, Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10.
- On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11.
- On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total value of $199,500.00.
NewAmsterdam Pharma Trading Up 3.0%
NASDAQ:NAMS opened at $30.77 on Tuesday. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The stock has a 50-day moving average price of $33.48 and a two-hundred day moving average price of $33.32. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of -17.79 and a beta of 0.04.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.
Institutional Investors Weigh In On NewAmsterdam Pharma
Several institutional investors have recently bought and sold shares of the company. Capital World Investors boosted its position in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company's stock worth $279,358,000 after acquiring an additional 1,434,986 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company's stock valued at $119,407,000 after purchasing an additional 1,252,451 shares during the last quarter. Duquesne Family Office LLC raised its holdings in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company's stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the last quarter. Castle Hook Partners LP bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $38,062,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Institutional investors own 89.89% of the company's stock.
Analysts Set New Price Targets
Several analysts have commented on NAMS shares. Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. HC Wainwright upgraded shares of NewAmsterdam Pharma to a "strong-buy" rating in a report on Thursday, February 19th. The Goldman Sachs Group increased their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a "neutral" rating in a research report on Tuesday, December 2nd. Wall Street Zen lowered shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a report on Saturday, February 21st. Finally, Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and an average price target of $47.10.
View Our Latest Research Report on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
